Top-Rated StocksTop-RatedNASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Forecast, Price & News $14.26 +0.26 (+1.86%) (As of 06/2/2023 08:47 PM ET) Add Compare Share Share Today's Range$13.73▼$14.3050-Day Range$13.29▼$17.5652-Week Range$5.74▼$19.94Volume925,500 shsAverage Volume2.53 million shsMarket Capitalization$2.29 billionP/E RatioN/ADividend YieldN/APrice Target$26.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability BridgeBio Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.7% Upside$26.63 Price TargetShort InterestHealthy11.46% of Float Sold ShortDividend StrengthN/ASustainability-2.31Upright™ Environmental ScoreNews Sentiment0.40Based on 4 Articles This WeekInsider TradingSelling Shares$3.78 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.38) to ($2.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.77 out of 5 starsMedical Sector46th out of 980 stocksPharmaceutical Preparations Industry18th out of 485 stocks 4.5 Analyst's Opinion Consensus RatingBridgeBio Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.63, BridgeBio Pharma has a forecasted upside of 86.7% from its current price of $14.26.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.46% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 6.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBridgeBio Pharma has received a 53.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Infigratinib", "Fosdenopterin", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for BridgeBio Pharma is -2.31. Previous Next 1.9 News and Social Media Coverage News SentimentBridgeBio Pharma has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BridgeBio Pharma this week, compared to 3 articles on an average week.Search InterestOnly 15 people have searched for BBIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,777,099.00 in company stock.Percentage Held by Insiders29.60% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.46% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.38) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About BridgeBio Pharma (NASDAQ:BBIO) StockBridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.Read More Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Stock News HeadlinesMay 31, 2023 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Sees Large Drop in Short InterestMay 30, 2023 | markets.businessinsider.comBridgeBio Pharma (BBIO) Gets a Buy from Bank of America SecuritiesJune 5, 2023 | Stansberry Research (Ad)Why 2023 Could Kick Off a "Cash Frenzy" in StocksBut the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.May 22, 2023 | finance.yahoo.comBridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 22, 2023 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Recommendation of "Buy" from AnalystsMay 21, 2023 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $722,243.52 in StockMay 17, 2023 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Trading Up 6.7%May 15, 2023 | finance.yahoo.comBridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual MeetingJune 5, 2023 | Stansberry Research (Ad)Why 2023 Could Kick Off a "Cash Frenzy" in StocksBut the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.May 15, 2023 | seekingalpha.comBridgeBio Pharma: A Lot Of Paths To Potential SuccessMay 12, 2023 | msn.comUnusual Call Option Trade in BridgeBio Pharma (BBIO) Worth $157.50KMay 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and NGM Biopharmaceuticals (NGM)May 9, 2023 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Given New $29.00 Price Target at MizuhoMay 8, 2023 | msn.comMizuho Maintains BridgeBio Pharma (BBIO) Buy RecommendationMay 8, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on BridgeBio Pharma (BBIO)May 5, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on BridgeBio Pharma (BBIO)May 5, 2023 | finance.yahoo.comPinning Down BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) P/S Is Difficult Right NowMay 4, 2023 | finance.yahoo.comBridgeBio Pharma Reports First Quarter 2023 Financial Results and Business UpdateMay 4, 2023 | msn.comBridgeBio Pharma: Q1 Earnings InsightsApril 27, 2023 | finance.yahoo.comBridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare ConferenceApril 27, 2023 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Buy" by BrokeragesApril 21, 2023 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Evercore ISIApril 21, 2023 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $15.15April 19, 2023 | msn.comEvercore ISI Group Initiates Coverage of BridgeBio Pharma (BBIO) with Outperform RecommendationApril 19, 2023 | americanbankingnews.comSVB Leerink Equities Analysts Raise Earnings Estimates for BridgeBio Pharma, Inc. (NASDAQ:BBIO)April 16, 2023 | americanbankingnews.comSVB Securities Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $27.00April 15, 2023 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up After Analyst UpgradeSee More Headlines BBIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBIO Company Calendar Last Earnings5/04/2023Today6/04/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BBIO CUSIPN/A CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees576Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.63 High Stock Price Forecast$40.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+86.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-481,180,000.00 Net Margins-546.34% Pretax Margin-547.77% Return on EquityN/A Return on Assets-73.98% Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual Sales$77.78 million Price / Sales29.43 Cash FlowN/A Price / Cash FlowN/A Book Value($7.56) per share Price / Book-1.89Miscellaneous Outstanding Shares160,501,000Free Float112,993,000Market Cap$2.29 billion OptionableNot Optionable Beta0.71 Key ExecutivesNeil KumarChief Executive Officer & DirectorJonathan C. FoxPresident & Chief Medical OfficerChristine E. SiuChief Operating OfficerBrian C. StephensonChief Financial Officer & SecretaryUma SinhaChief Scientific OfficerKey CompetitorsAkero TherapeuticsNASDAQ:AKROMirati TherapeuticsNASDAQ:MRTXAmphastar PharmaceuticalsNASDAQ:AMPHHarmony BiosciencesNASDAQ:HRMYNuvalentNASDAQ:NUVLView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCSold 8,124 shares on 6/1/2023Ownership: 0.010%ProShare Advisors LLCSold 3,030 shares on 5/26/2023Ownership: 0.014%Capital Impact Advisors LLCSold 5,003 shares on 5/23/2023Ownership: 0.017%Putnam Investments LLCBought 13,352 shares on 5/22/2023Ownership: 0.030%JPMorgan Chase & Co.Bought 8,000 shares on 5/18/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions BBIO Stock - Frequently Asked Questions Should I buy or sell BridgeBio Pharma stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BBIO shares. View BBIO analyst ratings or view top-rated stocks. What is BridgeBio Pharma's stock price forecast for 2023? 9 Wall Street analysts have issued 12-month price targets for BridgeBio Pharma's shares. Their BBIO share price forecasts range from $18.00 to $40.00. On average, they expect the company's share price to reach $26.63 in the next year. This suggests a possible upside of 86.7% from the stock's current price. View analysts price targets for BBIO or view top-rated stocks among Wall Street analysts. How have BBIO shares performed in 2023? BridgeBio Pharma's stock was trading at $7.62 at the beginning of 2023. Since then, BBIO stock has increased by 87.1% and is now trading at $14.26. View the best growth stocks for 2023 here. Are investors shorting BridgeBio Pharma? BridgeBio Pharma saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 13,290,000 shares, a drop of 6.4% from the April 30th total of 14,200,000 shares. Based on an average daily trading volume, of 3,140,000 shares, the short-interest ratio is currently 4.2 days. Currently, 11.5% of the shares of the stock are sold short. View BridgeBio Pharma's Short Interest. When is BridgeBio Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our BBIO earnings forecast. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its quarterly earnings results on Thursday, May, 4th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.09. The company had revenue of $1.83 million for the quarter, compared to analysts' expectations of $3.23 million. BridgeBio Pharma's revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.35) EPS. What ETFs hold BridgeBio Pharma's stock? ETFs with the largest weight of BridgeBio Pharma (NASDAQ:BBIO) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT). When did BridgeBio Pharma IPO? (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. What is BridgeBio Pharma's stock symbol? BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO." Who are BridgeBio Pharma's major shareholders? BridgeBio Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Hhlr Advisors LTD. (2.48%), Geode Capital Management LLC (1.40%), Perceptive Advisors LLC (1.19%), Pictet Asset Management SA (0.90%), Ensign Peak Advisors Inc (0.67%) and Charles Schwab Investment Management Inc. (0.58%). Insiders that own company stock include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Douglas A Dachille, Genetic Disorder LP Kkr, Michael Thomas Henderson, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BridgeBio Pharma's stock price today? One share of BBIO stock can currently be purchased for approximately $14.26. How much money does BridgeBio Pharma make? BridgeBio Pharma (NASDAQ:BBIO) has a market capitalization of $2.29 billion and generates $77.78 million in revenue each year. The company earns $-481,180,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. How many employees does BridgeBio Pharma have? The company employs 576 workers across the globe. How can I contact BridgeBio Pharma? BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The official website for the company is bridgebio.com. The company can be reached via phone at (650) 391-9740. This page (NASDAQ:BBIO) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.